Abstract
Inhibition of p53-MDM2/MDMX interaction is considered to be a promising strategy for anticancer drug design to activate wild-type p53 in tumors. We carry out molecular dynamics (MD) simulations to study the binding mechanisms of peptide and non-peptide inhibitors to MDM2/MDMX. The rank of binding free energies calculated by molecular mechanics generalized Born surface area (MM-GBSA) method agrees with one of the experimental values. The results suggest that van der Waals energy drives two kinds of inhibitors to MDM2/MDMX. We also find that the peptide inhibitors can produce more interaction contacts with MDM2/MDMX than the non-peptide inhibitors. Binding mode predictions based on the inhibitor-residue interactions show that the π–π, CH–π and CH–CH interactions dominated by shape complimentarity, govern the binding of the inhibitors in the hydrophobic cleft of MDM2/MDMX. Our studies confirm the residue Tyr99 in MDMX can generate a steric clash with the inhibitors due to energy and structure. This finding may theoretically provide help to develop potent dual-specific or MDMX inhibitors.
References
66
Referenced
23
10.1038/nrm2147
/ Nat. Rev. Mol. Cell Biol / p53 in health and disease by Vousden (2007)10.1016/S1097-2765(03)00529-X
/ Mol. Cell / Regulation of p53 by Mdm2: Fate Is in the Numbers by Shmueli (2004)10.1074/jbc.M213034200
/ J. Biol. Chem / Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2 by Little (2003)10.1038/sj.emboj.7601469
/ EMBO J / An essential function of the extreme C-terminus of MDM2 can be provided by MDMX by Uldrijan (2006)10.1073/pnas.0511130103
/ Proc. Natl. Acad. Sci. USA / Core domain interactions in full-length p53 in solution by Veprintsev (2006)10.4161/cc.9.6.10956
/ Cell Cycle / Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery by Popowicz (2010)10.1038/nature05529
/ Nature / Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas by Xue (2007)10.1038/nature05541
/ Nature / Restoration of p53 function leads to tumour regression in vivo by Ventura (2007)10.1016/j.cell.2006.12.007
/ Cell / Modeling the therapeutic efficacy of p53 restoration in tumors by Martins (2006)10.1074/jbc.C600147200
/ J. Biol. Chem / MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin by Hu (2006)10.1016/j.tcb.2010.01.009
/ Trends Cell Biol / The p53 orchestra: Mdm2 and Mdmx set the tone by Wade (2010)10.4161/cc.8.8.8185
/ Cell Cycle / High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx by Czarna (2009)10.1242/jcs.03362
/ J. Cell Sci / MDMX: From bench to bedside by Marine (2007)10.1038/sj.onc.1202281
/ Oncogene / Comparative study of the p53-mdm2 and p53-MDMX interfaces by Boettger (1999)10.1002/bip.20741
/ Biopolymers / Targeting protein–protein interactions: Lessons from p53/MDM2 by Murray (2007)10.1073/pnas.0900947106
/ Proc. Natl. Acad. Sci. USA / Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX by Pazgier (2009)10.1016/j.molmed.2006.11.002
/ Trends. Mol. Med / MDM2 inhibitors for cancer therapy by Vassilev (2007)10.1038/387296a0
/ Nature / Mdm2 promotes the rapid degradation of p53 by Haupt (1997)10.4161/cc.7.8.5754
/ Cell Cycle / The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to Mdm2 inhibitor-mediated apoptosis by Bixby (2008)10.1002/ddr.20261
/ Drug Dev. Res / New developments in small molecules targeting p53 pathways in anticancer therapy by Cheok (2008)10.1146/annurev.pharmtox.48.113006.094723
/ Annu. Rev. Pharmacol. Toxicol / Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: A novel approach for cancer therapy by Shangary (2009)10.1016/S0014-5793(99)00254-9
/ FEBS Lett / MDM2 interacts with MDMX through their RING finger domains by Tanimura (1999)10.1128/MCB.20.3.1001-1007.2000
/ Mol. Cell. Biol / MdmX protects p53 from Mdm2-mediated degradation by Jackson (2000)10.3390/ijms12010128
/ Int. J. Mol. Sci / Insight into a novel p53 single point mutation (G389E) by molecular dynamics simulations by Pirolli (2010)10.4161/cc.6.19.4740
/ Cell Cycle / Molecular basis for the inhibition of p53 by Mdmx by Popowicz (2007)10.4161/cc.9.6.11067
/ Cell Cycle / Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies by Joseph (2010)10.1016/j.jmb.2010.03.005
/ J. Mol. Biol / Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions by Li (2010)10.1016/j.jmgm.2011.07.003
/ J. Mol. Graph. Mod / Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based [alpha]-helix mimetic as dual inhibitors of MDM2 and MDMX by Lu (2011)10.1074/jbc.M109.056747
/ J. Biol. Chem / Identification and characterization of the first small molecule inhibitor of MDMX by Reed (2010)10.1021/ci100113p
/ J. Chem. Inf. Model / Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction by Dezi (2010)10.1074/jbc.M109.073056
/ J. Biol. Chem / Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX by Phan (2010)10.1074/jbc.M809096200
/ J. Biol. Chem / Crystal structures of human MdmX (HdmX) in complex with p53 peptide analogues reveal surprising conformational changes by Kallen (2009)10.1007/s10822-010-9366-0
/ J. Comput. Aided Mol. Des / A computational analysis of the binding model of MDM2 with inhibitors by Hu (2010)10.1002/prot.20275
/ Proteins / Computational studies and peptidomimetic design for the human p53–MDM2 complex by Zhong (2005)10.1007/BF00124361
/ J. Comput. Aided Mol. Des / Computer-aided drug design: A free energy perturbation study on the binding of methyl-substituted pterins and N5-deazapterins to dihydrofolate reductase by Cummins (1993)10.1002/jcc.20111
/ J. Comput. Chem / Prediction of pKa shifts in proteins using a combination of molecular mechanical and continuum solvent calculations by Kuhn (2004)10.1002/jcc.21268
/ J. Comput. Chem / Trypsin ligand binding free energies from explicit and implicit solvent simulations with polarizable potential by Jiao (2009)10.1021/ja003834q
/ J. Am. Chem. Soc / Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA by Wang (2001)10.1006/jmbi.2000.4057
/ J. Mol. Biol / Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model1 by Wang (2000)10.1021/ja003164o
/ J. Am. Chem. Soc / An analysis of the interactions between the Sem-5 SH3 domain and its ligands using molecular dynamics, free energy calculations, and sequence analysis by Wang (2001)10.1016/S0006-3495(04)74084-9
/ Biophys. J / Revisiting free energy calculations: A theoretical connection to MM/PBSA and direct calculation of the association free energy by Swanson (2004)10.1021/ja909575j
/ J. Am. Chem. Soc / Electrostatic polarization makes a substantial contribution to the free energy of avidin-biotin binding by Tong (2010)10.1016/j.jmgm.2011.06.003
/ J. Mol. Graph. Model / Insight into Mechanism of small molecule inhibitors of the MDM2-p53 interaction: Molecular dynamics simulation and free energy analysis by Chen (2011)10.1007/s00894-009-0553-7
/ J. Mol. Model / Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: Free energy calculation and molecular dynamic simulation by Chen (2010)10.1002/chem.200800277
/ Chem. Eur. J / Selectivity of neutral/weakly basic P1 group inhibitors of thrombin and trypsin by a molecular dynamics study by Wu (2008)10.1021/jm0609162
/ J. Med. Chem / Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: Mechanism for binding and drug resistance by Hou (2007)10.1002/prot.21044
/ Proteins / A computational analysis of the binding affinities of FKBP12 inhibitors using the MM PB/SA method by Xu (2006)10.1002/prot.20033
/ Proteins / Exploring protein native states and large-scale conformational changes with a modified generalized born model by Onufriev (2004)10.1021/jp961710n
/ J. Phys. Chem / Parametrized models of aqueous free energies of solvation based on pairwise descreening of solute atomic charges from a dielectric medium by Hawkins (1996)10.1021/ct600085e
/ J. Chem. Theory. Comput / Generalized Born model with a simple, robust molecular volume correction by Mongan (2007)10.1021/jp066745u
/ J. Phys.Chem. A / Insights into the strength and origin of halogen bonding: The halobenzene-formaldehyde dimer by Riley (2007)10.1002/jcc.20788
/ J. Comput. Chem / Efficient bond function basis set for interaction energies by Ding (2008)10.1016/j.jmb.2006.08.007
/ J. Mol. Biol / Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114 by Kovalevsky (2006)10.1021/jm050943c
/ J. Med. Chem / Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M by Kovalevsky (2006)- Case, D.A., Darden, T.A., Cheatham, T.E., Simmerling, I.C.L., Wang, J., Duke, R.E., Luo, R., Crowley, M., Walker, R.C., and Zhang, W. (2008). AMBER 10, University of California, San Francisco.
- Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Zakrzewski, V.G., Montgomery, J.A., Stratmann, R.E., and Burant, J.C. (1998). Gaussian 98, Gaussian, Inc.
10.1002/jcc.540161106
/ J. Comput. Chem / Application of the multimolecule and multiconformational RESP methodology to biopolymers: Charge derivation for DNA, RNA, and proteins by Cieplak (1995)10.1002/jcc.20035
/ J. Comput. Chem / Development and testing of a general amber force field by Wang (2004)10.1063/1.445869
/ J. Chem. Phys / Comparison of simple potential functions for simulating liquid water by Jorgensen (1983)10.1007/BF02367312
/ Ann. Biomed. Eng / Numerical integration by Coleman (1977)10.1063/1.464397
/ J. Chem. Phys / Particle mesh Ewald: An N log (N) method for Ewald sums in large systems by Darden (1993)10.1063/1.470117
/ J. Chem. Phys / A smooth particle mesh Ewald method by Essmann (1995)10.1107/S0021889883010985
/ J. Appl. Cryst / Analytical molecular surface calculation by Connolly (1983)10.1371/journal.pone.0010742
/ PLoS One / The role of Phe82 and Phe351 in auxin-induced substrate perception by TIR1 ubiquitin ligase: A novel insight from molecular dynamics simulations by Hao (2010)10.1016/S0022-2836(03)00610-7
/ J. Mol. Biol / Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes by Gohlke (2003)10.1021/ja990935j
/ J. Am. Chem. Soc / Computational alanine scanning to probe protein-protein interactions: a novel approach to evaluate binding free energies by Massova (1999)
Dates
Type | When |
---|---|
Created | 13 years, 6 months ago (Feb. 17, 2012, 11:01 a.m.) |
Deposited | 1 year, 2 months ago (May 30, 2024, 6:48 p.m.) |
Indexed | 2 months ago (June 16, 2025, 1:43 a.m.) |
Issued | 13 years, 6 months ago (Feb. 17, 2012) |
Published | 13 years, 6 months ago (Feb. 17, 2012) |
Published Online | 13 years, 6 months ago (Feb. 17, 2012) |
@article{Chen_2012, title={Computational Studies of Difference in Binding Modes of Peptide and Non-Peptide Inhibitors to MDM2/MDMX Based on Molecular Dynamics Simulations}, volume={13}, ISSN={1422-0067}, url={http://dx.doi.org/10.3390/ijms13022176}, DOI={10.3390/ijms13022176}, number={2}, journal={International Journal of Molecular Sciences}, publisher={MDPI AG}, author={Chen, Jianzhong and Zhang, Dinglin and Zhang, Yuxin and Li, Guohui}, year={2012}, month=feb, pages={2176–2195} }